Cost-effectiveness of ivosidenib versus chemotherapy for previously treated IDH1-mutant advanced intrahepatic cholangiocarcinoma in Taiwan

Abstract Background International guidelines recommend ivosidenib followed by modified FOLFOX (mFOLFOX) for advanced intrahepatic cholangiocarcinoma (ICC) with isocitrate dehydrogenase 1 (IDH1) mutations. Taiwan National Health Insurance covers only fluorouracil/leucovorin (5-FU/LV) chemotherapy for...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Kuei-An Chen, Wei-Ming Huang, Eric Yi-Ting Chen, Pei-Kuan Ho, Chen-Han Chueh, Yu-Wen Wen, Ming-Huang Chen, Nai-Jung Chiang, Yi-Wen Tsai
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	BMC 2024-05-01
Schriftenreihe:	BMC Cancer
Schlagworte:	Ivosidenib Cost-effectiveness Advanced intrahepatic cholangiocarcinoma IDH1 mutations
Online-Zugang:	https://doi.org/10.1186/s12885-024-12362-y
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!